I. Matte

发表

Ovarian cancer ascites enhance the migration of patient‐derived peritoneal mesothelial cells via cMet pathway through HGF‐dependent and ‐independent mechanisms

C. Rancourt, A. Piché, D. Lane, 2015, International journal of cancer.

Ascites in Ovarian Cancer Progression: Opportunities for Biomarker Discovery and New Avenues for Targeted Therapies

A. Piché, P. Bessette, I. Matte, 2017 .

Targeted ovarian cancer treatment: the TRAILs of resistance.

C. Rancourt, A. Piché, D. Lane, 2012, American journal of cancer research.

Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail.

C. Rancourt, A. Piché, I. Matte, 2015, International journal of oncology.

Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients

C. Rancourt, A. Piché, D. Lane, 2011, BMC Cancer.

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling

C. Rancourt, A. Piché, D. Lane, 2016, Molecular Cancer.

Specimen quality evaluation in Canadian biobanks participating in the COEUR repository.

C. Le Page, A. Mes-Masson, D. Huntsman, 2013, Biopreservation and biobanking.

Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis

C. Rancourt, A. Piché, D. Lane, 2013, Journal of Ovarian Research.

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

C. Rancourt, A. Piché, D. Lane, 2015, BMC Cancer.

Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis

C. Rancourt, A. Piché, D. Lane, 2012, Molecular Cancer.

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis

C. Rancourt, A. Piché, D. Lane, 2012, Journal of Ovarian Research.

The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells

C. Rancourt, A. Piché, D. Lane, 2010, Oncogene.

The Role of MUC16 Mucin (CA125) in the Pathogenesis of Ovarian Cancer

C. Rancourt, A. Piché, D. Lane, 2012 .

Profiling of cytokines in human epithelial ovarian cancer ascites.

C. Rancourt, A. Piché, D. Lane, 2012, American journal of cancer research.

Ascites IL-10 Promotes Ovarian Cancer Cell Migration

A. Piché, D. Lane, P. Bessette, 2018, Cancer Microenvironment.

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling

C. Rancourt, A. Piché, D. Lane, 2016, Molecular Cancer.

Antiapoptotic Proteins Bcl-2 and Bcl-XL Inhibit Clostridium difficile Toxin A-Induced Cell Death in Human Epithelial Cells

C. Asselin, A. Piché, L. Fortier, 2009, Infection and Immunity.

Serum CA 125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer

A. Piché, P. Bessette, Perrine Garde-Granger, 2019 .

Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer.

A. Piché, P. Bessette, Perrine Garde-Granger, 2019, American journal of cancer research.

The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer

C. Rancourt, A. Piché, D. Lane, 2010, Journal of ovarian research.

MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling.

C. Rancourt, A. Piché, I. Matte, 2015, American journal of cancer research.

MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.

Maxime Pinard, C. Rancourt, A. Piché, 2011, Gynecologic oncology.

Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway

A. Piché, P. Bessette, Perrine Garde-Granger, 2019, BMC cancer.

Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions

C. Rancourt, A. Piché, P. Bessette, 2016, Clinical & Experimental Metastasis.

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression

C. Rancourt, A. Piché, D. Lane, 2014, BMC Cancer.

Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells

C. Rancourt, A. Piché, M. Boivin, 2011, British Journal of Cancer.

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression

C. Rancourt, A. Piché, D. Lane, 2014, BMC Cancer.

Biological Significance of Apoptosis in Ovarian Cancer: TRAIL Therapeutic Targeting

C. Rancourt, A. Piché, D. Lane, 2013 .

Role of malignant ascites on human mesothelial cells and their gene expression profiles

D. Bachvarov, C. Rancourt, A. Piché, 2014, BMC Cancer.

Role of malignant ascites on human mesothelial cells and their gene expression profiles

D. Bachvarov, C. Rancourt, A. Piché, 2014, BMC Cancer.

Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway

A. Piché, P. Bessette, Perrine Garde-Granger, 2019, BMC Cancer.